Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Human herpesviruses frequently cause infections in solid organ transplant (SOT) recipients. Areas covered: We provide an overview of the clinical impact of alpha and beta herpesviruses and highlight the mechanisms of action, pharmacokinetics, clinical indications, and adverse effects of antiviral drugs for the management of herpes simplex virus, varicella zoster virus and cytomegalovirus. We comprehensively evaluated key clinical trials that led to drug approval, and served as the foundation for management guidelines. We further provide an update on investigational antiviral agents for alpha and beta herpesvirus infections after SOT. Expert commentary: The therapeutic armamentarium for herpes infections is limited by the emergence of drug resistance. There have been major efforts for discovery of new drugs against these viruses, but the results of early-phase clinical trials have been less than encouraging. We believe, however, that more antiviral drug options are needed given the adverse side effects associated with current antiviral agents, and the emergence of drug-resistant virus populations in SOT recipients. Likewise, optimized use and strategies are needed for existing and novel antiviral drugs against alpha and beta-herpesviruses in SOT recipients.

Original languageEnglish (US)
Pages (from-to)93-110
Number of pages18
JournalExpert Review of Anti-Infective Therapy
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Herpesviridae Infections
Antiviral Agents
Herpesviridae
Transplants
Clinical Trials
Viruses
Therapeutics
Drug Approval
Human Herpesvirus 3
Simplexvirus
Drug Discovery
Infection
Cytomegalovirus
Drug Resistance
Pharmacokinetics
Transplant Recipients
Guidelines
Pharmaceutical Preparations
Population

Keywords

  • Herpesvirus
  • infection
  • solid organ transplant

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients. / Abad, C. L.; Razonable, Raymund R.

In: Expert Review of Anti-Infective Therapy, Vol. 15, No. 2, 01.02.2017, p. 93-110.

Research output: Contribution to journalReview article

@article{73bbcc57d4fd4c6197c4f49b0786e936,
title = "Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients",
abstract = "Introduction: Human herpesviruses frequently cause infections in solid organ transplant (SOT) recipients. Areas covered: We provide an overview of the clinical impact of alpha and beta herpesviruses and highlight the mechanisms of action, pharmacokinetics, clinical indications, and adverse effects of antiviral drugs for the management of herpes simplex virus, varicella zoster virus and cytomegalovirus. We comprehensively evaluated key clinical trials that led to drug approval, and served as the foundation for management guidelines. We further provide an update on investigational antiviral agents for alpha and beta herpesvirus infections after SOT. Expert commentary: The therapeutic armamentarium for herpes infections is limited by the emergence of drug resistance. There have been major efforts for discovery of new drugs against these viruses, but the results of early-phase clinical trials have been less than encouraging. We believe, however, that more antiviral drug options are needed given the adverse side effects associated with current antiviral agents, and the emergence of drug-resistant virus populations in SOT recipients. Likewise, optimized use and strategies are needed for existing and novel antiviral drugs against alpha and beta-herpesviruses in SOT recipients.",
keywords = "Herpesvirus, infection, solid organ transplant",
author = "Abad, {C. L.} and Razonable, {Raymund R}",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/14787210.2017.1266253",
language = "English (US)",
volume = "15",
pages = "93--110",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients

AU - Abad, C. L.

AU - Razonable, Raymund R

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction: Human herpesviruses frequently cause infections in solid organ transplant (SOT) recipients. Areas covered: We provide an overview of the clinical impact of alpha and beta herpesviruses and highlight the mechanisms of action, pharmacokinetics, clinical indications, and adverse effects of antiviral drugs for the management of herpes simplex virus, varicella zoster virus and cytomegalovirus. We comprehensively evaluated key clinical trials that led to drug approval, and served as the foundation for management guidelines. We further provide an update on investigational antiviral agents for alpha and beta herpesvirus infections after SOT. Expert commentary: The therapeutic armamentarium for herpes infections is limited by the emergence of drug resistance. There have been major efforts for discovery of new drugs against these viruses, but the results of early-phase clinical trials have been less than encouraging. We believe, however, that more antiviral drug options are needed given the adverse side effects associated with current antiviral agents, and the emergence of drug-resistant virus populations in SOT recipients. Likewise, optimized use and strategies are needed for existing and novel antiviral drugs against alpha and beta-herpesviruses in SOT recipients.

AB - Introduction: Human herpesviruses frequently cause infections in solid organ transplant (SOT) recipients. Areas covered: We provide an overview of the clinical impact of alpha and beta herpesviruses and highlight the mechanisms of action, pharmacokinetics, clinical indications, and adverse effects of antiviral drugs for the management of herpes simplex virus, varicella zoster virus and cytomegalovirus. We comprehensively evaluated key clinical trials that led to drug approval, and served as the foundation for management guidelines. We further provide an update on investigational antiviral agents for alpha and beta herpesvirus infections after SOT. Expert commentary: The therapeutic armamentarium for herpes infections is limited by the emergence of drug resistance. There have been major efforts for discovery of new drugs against these viruses, but the results of early-phase clinical trials have been less than encouraging. We believe, however, that more antiviral drug options are needed given the adverse side effects associated with current antiviral agents, and the emergence of drug-resistant virus populations in SOT recipients. Likewise, optimized use and strategies are needed for existing and novel antiviral drugs against alpha and beta-herpesviruses in SOT recipients.

KW - Herpesvirus

KW - infection

KW - solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=85009450677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009450677&partnerID=8YFLogxK

U2 - 10.1080/14787210.2017.1266253

DO - 10.1080/14787210.2017.1266253

M3 - Review article

C2 - 27911112

AN - SCOPUS:85009450677

VL - 15

SP - 93

EP - 110

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 2

ER -